GlassScriptPhysician profile
Tracey Aude
NPI 1487734448
$2,001.61
in general payments reported to CMS, 2019-2025
18 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $312 · 2023: $646 · 2024: $448 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $351.81 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $274.22 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Amgen INC. | $264.85 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $196.20 | 2021-2025 | Farapulse, Ingevity+ |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.71 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $154.09 | 2021-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.40 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $99.98 | 2022-2023 | Opsumit |
| Merck Sharp & Dohme LLC | $86.49 | 2023-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $49.20 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $48.84 | 2025 | Onpattro |
| Edwards Lifesciences Corporation | $37.52 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lexicon Pharmaceuticals, INC. | $34.54 | 2024 | |
| Baxter Healthcare | $32.38 | 2025 | Biopharma Sol - Contract Manuf |
| Pfizer INC. | $29.93 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $27.86 | 2024 | Arcalyst |
| Medtronic, INC. | $22.53 | 2023 | Reveal Linq |
| Lilly USA, LLC | $20.06 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Aude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.